by Michael Fenimore | May 28, 2021 | Uncategorized
Patients with Fabry disease (FD) have a significantly shorter life expectancy compared to the general population, often due to cardiac or renal complications of this rare disease. There are only 2 approved therapies for FD—enzyme replacement therapy and chaperone...
by Michael Fenimore | Apr 9, 2021 | Uncategorized
The overall goal of this CE initiative is to establish meaningful, small group interactions between clinicians involved in the care of patients with breast cancer that will, through a variety of collaborative educational experiences, help them optimally manage...
by Michael Fenimore | Mar 16, 2021 | Uncategorized
Osteoarthritis and Pain: Intensive Training in Pain Management is a comprehensive evidence-based presentation about the burden of osteoarthritis (OA) and OA pain, the challenges of current pharmacologic and nonpharmacologic strategies, and evidence about the role of...
by Michael Fenimore | Mar 15, 2021 | Uncategorized
MS is the leading cause of non-traumatic disability in adults over the age of 50 and has become a focus of evolving research. In just the past two decades, a greater understanding of the pathogenesis of MS has led to a litany of new FDA approved therapies. In fact,...
by Michael Fenimore | Mar 10, 2021 | Uncategorized
There is an urgent and ongoing need to provide cancer care professionals with guidance, training, and support during the COVID-19 pandemic as they respond to unprecedented challenges in maintaining high-quality patient care. Members of the care team are challenged by...
